Type 2 diabetes and obesity, might also have the potential to slow down the aging process. This groundbreaking discovery highlights the broader benefits of Semaglutide, also known by its brand name, Ozempic.
According to Professor Harlan Krumholz from the Yale School of Medicine, “Semaglutide has far-reaching benefits beyond what we initially imagined.” This statement follows the publication of several new studies that indicate the drug’s potential to treat a wide range of illnesses, including heart failure, arthritis, Alzheimer’s, and even cancer.
“It wouldn’t surprise me that improving people’s health this way actually slows down the aging process,” Prof. Krumholz said during the European Society of Cardiology Conference 2024, where these studies were presented.
The new data, published in prominent medical journals like the Journal of the American College of Cardiology (JACC), demonstrates how these medications could revolutionize cardiovascular care and significantly enhance overall cardiovascular health.
The studies, part of the Select trial, monitored over 17,600 individuals aged 45 or older. These participants, who were obese or overweight and had cardiovascular disease but not diabetes, were given either 2.4 mg of Semaglutide or a placebo for more than three years. The results were remarkable—those taking Semaglutide showed a lower mortality rate from all causes, including cardiovascular issues and Covid-19.
Interestingly, while participants who took Semaglutide were just as likely to contract Covid-19 as those who took a placebo, they were less likely to die from the virus. Specifically, 2.6% of those on Semaglutide died, compared to 3.1% of those on the placebo. Moreover, the drug consistently reduced the risk of adverse cardiovascular outcomes regardless of sex and improved heart failure symptoms, cutting inflammation levels in the body, irrespective of weight loss.
Dr. Benjamin Scirica, the lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, stated that the findings “reinforce that overweight and obesity increases the risk of death due to many etiologies.” However, he emphasized that this risk “can be modified with potent incretin-based therapies like Semaglutide.”
Semaglutide is currently available by prescription through the NHS under the brand names Wegovy (for obesity) and Ozempic (for diabetes). It works by mimicking the hormone GLP-1, making users feel fuller and less hungry, which aids in weight management.
While this drug shows great promise, experts caution that it is not a quick fix or a substitute for a healthy lifestyle. Proper medical supervision is essential when using Semaglutide, as it can have side effects, including nausea, upset stomach, bloating, and gas.
How to get this Drugs?
If you are interested in sourcing Semaglutide, you can obtain this product through contacting our team.
Email – info@pdluk.com
Website – https://www.pdluk.com
Please note that we only deals with Healthcare professionals and registered wholesalers
Article Source – https://www.bbc.co.uk/news/articles/ce81j919gdjo.amp